Dual-Drug Containing Core-Shell Nanoparticles for Lung Cancer Therapy

Late-stage diagnosis of lung cancer occurs ~95% of the time due to late manifestation of its symptoms, necessitating rigorous treatment following diagnosis. Existing treatment methods are limited by lack of specificity, systemic toxicity, temporary remission, and radio-resistance in lung cancer cell...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Sci Rep
Autors principals: Menon, Jyothi U., Kuriakose, Aneetta, Iyer, Roshni, Hernandez, Elizabeth, Gandee, Leah, Zhang, Shanrong, Takahashi, Masaya, Zhang, Zhang, Saha, Debabrata, Nguyen, Kytai T.
Format: Artigo
Idioma:Inglês
Publicat: Nature Publishing Group UK 2017
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5643549/
https://ncbi.nlm.nih.gov/pubmed/29038584
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-017-13320-4
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars